Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model

  • Authors:
    • Carl Wibom
    • Maria Sandström
    • Roger Henriksson
    • Henrik Antti
    • Mikael Johansson
    • A. Tommy Bergenheim
  • View Affiliations

  • Published online on: October 1, 2010     https://doi.org/10.3892/ijo_00000739
  • Pages: 879-890
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The treatment of glioblastoma is unsatisfactory. Improved understanding of the biological effects of treatment, together with development of new tools to predict outcome of the initiated treatment are therefore of great need. Vandetanib (ZD6474) is mainly a vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) receptor tyrosine kinase inhibitor. This study investigated the pattern of protein expression in brain tumor and normal brain tissue, following treatment with vandetanib in a rat glioma model. BT4C-cells were stereotactically implanted into the brain of BD IX rats. The rats were divided into three different experiments. The treatment schedule for experiments one and two consisted of daily, oral doses of vandetanib from day 6 until day 12 or 20 after implantation, respectively. In the third experiment, each animal received a single dose of vandetanib on day 19 after implantation and was then sacrificed 2, 8 or 24 h thereafter. The protein expression profiles were analyzed by SELDI-TOF-MS and evaluated with multivariate statistical methods. Following treatment with vandetanib, we found significantly altered protein expression pattern in malignant glioma and normal brain. Analyzing protein spectra is an interesting option to assess biological effects induced in brain tissue by signal transduction inhibitors such as vandetanib.

Related Articles

Journal Cover

October 2010
Volume 37 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wibom C, Sandström M, Henriksson R, Antti H, Johansson M and Bergenheim AT: Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model. Int J Oncol 37: 879-890, 2010
APA
Wibom, C., Sandström, M., Henriksson, R., Antti, H., Johansson, M., & Bergenheim, A.T. (2010). Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model. International Journal of Oncology, 37, 879-890. https://doi.org/10.3892/ijo_00000739
MLA
Wibom, C., Sandström, M., Henriksson, R., Antti, H., Johansson, M., Bergenheim, A. T."Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model". International Journal of Oncology 37.4 (2010): 879-890.
Chicago
Wibom, C., Sandström, M., Henriksson, R., Antti, H., Johansson, M., Bergenheim, A. T."Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model". International Journal of Oncology 37, no. 4 (2010): 879-890. https://doi.org/10.3892/ijo_00000739